Influenza Research Grant
Solvay Pharmaceuticals Influenza Research Grant
Call for grant proposals (2009)
The Solvay Pharmaceuticals Influenza Research Grant is an independent grant established to support the
global advancement of influenza research. Each year, the topic will be selected by a committee of external
experts in the field of influenza. The Committee will independently judge and choose the grant recipient
based on agreed criteria.
Subject of the 2009 research proposal
Mode of action of adjuvants for influenza vaccines
Research background for the 2009 proposal
Avian influenza viruses, particularly H5N1 viruses, pose a well-documented threat for the next influenza pandemic. Such a
potential societal disaster can best be controlled by the timely use of pre-pandemic vaccines and/or pandemic vaccines.
Early research on such vaccines has demonstrated that non-adjuvanted H5N1 vaccine formulations are poorly
immunogenic and require high doses of antigen for an effective dose regimen. High-dosed pandemic vaccines offer no
realistic solution due to serious production-associated constraints.
Various adjuvanted vaccine formulations, with differing degrees of ‘antigen sparing’, have been developed in order to
reduce the required antigenic content of pandemic vaccines. However, for many adjuvants used in vaccinology, there is
little information on the mode of action to exert their adjuvanticity.
The 2009 Solvay Pharmaceuticals Influenza Research Grant will consider either new or existing research projects working
to better understand the mode of action of different classes of adjuvants.
The successful applicant will receive an amount of €50,000 for 2009. This would usually be paid in two stages; 50% on
confirmation of the grant award and 50% on submission of an executive summary to the independent Solvay
Pharmaceuticals Influenza Research Grant Committee. The 2009 Committee is comprised of three external experts,
including Chair, Professor Jonathan Van-Tam (University of Nottingham) with support from Bram Palache (Solvay
Biologicals). Although Solvay will have access to the applications, including proposals, it will not be involved in the
selection of the recipient.
Applications will only be considered from individuals or groups who are researchers or employees of academic
institutions, research institutions, public health institutes or hospitals. There are no geographical restrictions.
The Committee will consider relevant applications to fund new or existing projects, however, a project that is co-funded
by an industry sponsor will not be considered.
Applications will not be considered from members of the Committee, their Department or their family members.
More than one application can be submitted by an individual or institute.
Candidates should complete a grant application form and submit it by e-mail to the Solvay Pharmaceuticals Influenza
Research Grant Committee (firstname.lastname@example.org) on or before midnight on 28 November 2008.
Applications will be peer-reviewed by the Committee and assessed using the following core criteria.
• Significance of the research: What gaps in knowledge will be addressed by the project?
• Feasibility of success: Is it likely that the proposed project will achieve the research objectives within the
• Quality of research project: What is the quality of the submission?
Please note that applicants must not lobby members of the Committee, nor submit additional information in support of an
application after the original submission date. To do so may result in the application being withdrawn.
Awardees must be prepared to fulfil the following requirements.
• Provide an interim presentation to the Committee (no later than 6 months after award of the grant).
• Present the research results in the form of a poster, abstract or presentation at a recognized scientific conference
(no later than 12 months after award of the grant). Solvay Pharmaceuticals may, at the time, consider additional
requests for funding or contributing to costs for attendance at the conference.
• Notify the Committee of any presentations and/or scientific publications resulting from the research award.
• Acknowledge the grant award in any internal or external publications, posters, abstracts or presentations resulting
from the research.
• Provide the Committee with 10 reprints of any publication(s) resulting from the research.
• Allow Solvay Pharmaceuticals to disclose the grant award and recipient within their internal and external
The Committee will assess all grant applications submitted. Successful applicants will be notified by 16 January 2009.
The grant will be awarded on or before 2 February 2009.
Intellectual property considerations
Participating institutions are expected to have appropriate policies and procedures in place to identify, protect and manage
intellectual property potentially arising from the research. Discussions regarding details of intellectual property will be held
with successful applicants.
For more information, please contact: email@example.com.